| Name | Title | Contact Details |
|---|
BenefitHelp brings a menu of innovative solutions to help employers control costs and achieve a healthier, happier, more productive workforce. We use proven processes and technologies that help employers communicate, enroll, and administer their employee benefits programs. BenefitHelp has a range of services that address the entire benefit package, multi-media communication tools like the BenefitMOVIE www.BenefitMOVIE.com, multiple enrollment solutions, and a full benefit administration systems. Todays environment mandates that employers and employees become more educated consumers of Health Care & Benefit Plans. Our goal is to enhance the value of businesses by providing them innovative solutions that bring cost savings, education and benefit enrichment. As stated by Mark Holland, CEO,: "With our service everybody wins. Employers benefit because the employees better understand and appreciate their benefit package, as well as how much the employer spends; and employees benefit because they now understand and appreciate their benefits and how to use them." Studies show that people generally remember 10% of what they read, 10% of what they hear, 30% of what they see, and 50% of what they see and hear. Our multimedia approach provides the optimal solution because employees are reading, seeing, and hearing about their benefits. Visit us: www.BenefitHELP.com www.BenefitHELP.com/HowWeHelp.aspx www.BenefitMOVIE.com
Hadron is a premier A- VIII rated international hybrid fronting carrier, dedicated to transforming the insurance landscape for SMEs and lower middle-market insureds. As a modern market entrant, Hadron boasts a robust backing of $250 million in capital, and a strategic partnership network within the Altamont family. Hadron is an unencumbered, clean insurance entity specializing in custom insurance solutions for todays risk landscape. Our commitment to excellence is demonstrated in our top-tier operational frameworks and cutting-edge technology built to exceed expectations of partners and clients.
Unison Risk Advisors is one of the top privately-held insurance brokerages in the nation. Through its regional operating companies, Unison Risk Advisors provides risk management services, commercial property and casualty insurance, employee benefits and health insurance, personal and life insurance, and retirement plan services to corporate and individual clients in a diverse set of industries. Unison Risk Advisors is committed to an independent brokerage service model guided by the belief that clients are best served by professionally managed and well-resourced firms that can act independently upon the best interests of the client.
Liverpool Football Club was founded in 1892 and is one of the worlds most historic and famous football clubs. Honours include 19 League Titles, eight FA Cups, ten League Cups, six European Cups, three UEFA Cups, four European Super Cups, 16 Charity Shields, one FIFA Club World Cup, two Womens Super League and one Womens Championship. As a socially responsible club, Liverpool FC is proud of its heritage and plays a proactive role in its communities through its official charity, Liverpool FC Foundation, which helps children and families in Merseyside and beyond, and the Red Neighbours programme, which creates events and experiences specifically aimed at improving the lives of those living in and around the Anfield area (L4, L5 and L6). Liverpool FC is a global brand and works with leading edge commercial partners around the world providing unparalleled commercial opportunities.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.